Monday, 21 Oct 2019

Biologic/Novel Rx

Datesort ascending Type Title Save
12 Oct 2019 Slide of the day Adverse Effects of Newer Agents 2019
09 Oct 2019 Social RT @BharatKumarMD: How I feel when I switch a patient from a biologic to a biosimilar. #Rheum https://t.co/6pbdJ3u3U6
08 Oct 2019 News Biologics Lead the Way in Drug Price Increases
30 Sep 2019 News Ustekinumab Efficacy in Ulcerative Colitis
30 Sep 2019 News FDA Approves Rituximab for Children with GPA
27 Sep 2019 Social Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec
23 Sep 2019 Slide of the day Biologic Injection Site Reactions
17 Sep 2019 News Anakinra Shows Benefits in Cytokine Storm
13 Sep 2019 News Prior Authorizations Delay Care in Rheumatology
27 Aug 2019 Social Olumiant (baricitinib) meets its primary endpoint in a phase 3 trial in moderate to severe atopic dermatitis (AD). The BREEZE-AD7 study is one of 5 phase 3 studies in the BREEZE-AD programme. https://t.co/FOO2bIzeVA
27 Aug 2019 Social Positive safety and efficacy results for subcutaneous infliximab biosimilar, CT-P13 (Remsima), was presented at EULAR 2019. In 48 RA pts, efficacy (DAS28,, ACR20) of CT-P13 SC was comparable to CT-P13-IV up to Week 54. https://t.co/84ismy7ci2
19 Aug 2019 Social Abbvie has announced that the annual price for its new FDA approved JAK1 inhibitor, Rinvoq, will be $59,000. https://t.co/22LIetdTUh
16 Aug 2019 News Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis
14 Aug 2019 Social Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK
13 Aug 2019 Social RT @RheumNow: In GCA/Temporal arteritis, when do you start a DMARD/Biologic?
12 Aug 2019 Social In GCA/Temporal arteritis, when do you start a DMARD/Biologic?
09 Aug 2019 Social Amgen wins U.S. patent battle against Novartis over Enbrel patents, delaying Novartis' attempts to launch its etanercept biosimilar Erelzi until (possibly) 2029. Novartis intends to appeal. https://t.co/uoEQJJUf9A
06 Aug 2019 News Are Non-TNF Biologics Superior to TNF inhibitors?
06 Aug 2019 Social FDA has approved Turalio (pexidartinib) for the treatment of adults with the rare disorder, tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. https://t.co/eMTmFSW97A
04 Aug 2019 Social Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY